Second generation drug-eluting stent system challenges current gold standard

While research shows that drug-eluting stents effectively reduce restenosis and revascularization compared to bare-metal stents, questions and controversy surrounding the safety and efficacy of drug-eluting stents continue to dominate discussions and headlines. A study presented at the American College of Cardiology’s Innovation in Intervention: i2 Summit surveys the safety and efficacy of the second generation Xience™V Everolimus Eluting Coronary Stent System (EES), compared to the current gold standard paclitaxel-eluting stent (PES), to determine if it offers similar or enhanced outcomes. Innovation in Intervention: i2 Summit is an annual meeting for practicing cardiovascular...

Want to see the full article?

• Purchase this article for only $3.00